BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38908364)

  • 1. It is time to reconsider the use of naturally-occurring endotoxins in endotoxin recovery studies: Part 2 of a BioPhorum harmonized endotoxin recovery study.
    Bolden J; Knight M; Montz J; One J; Stockman S; Jones SP
    Biologicals; 2024 Jun; 87():101779. PubMed ID: 38908364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample Treatments That Solve Low Endotoxin Recovery Issues.
    Tsuchiya M
    PDA J Pharm Sci Technol; 2019; 73(5):433-442. PubMed ID: 30902837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a harmonized endotoxin recovery study protocol evaluation by 14 BioPhorum Operations Group (BPOG) member companies.
    Bolden J; Knight M; Stockman S; Omokoko B
    Biologicals; 2017 Jul; 48():74-81. PubMed ID: 28549938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biophysical Analysis of Lipopolysaccharide Formulations for an Understanding of the Low Endotoxin Recovery (LER) Phenomenon.
    Correa W; Brandenburg K; Zähringer U; Ravuri K; Khan T; von Wintzingerode F
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supramolecular assembly of micellar aggregates is the basis of low endotoxin recovery (LER) in a drug formulation that can be resolved by a whole blood assay.
    Schromm AB; Correa W; Gisch N; Steiniger F; Richter W; Martinez-de-Tejada G; Brandenburg K; von Wintzingerode F
    Biomed Pharmacother; 2024 Apr; 173():116286. PubMed ID: 38401515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of different sample treatment methods on Low Endotoxin Recovery Phenomenon.
    Bu R; Deng X; Cao Y; Jin J; Mai B; Meng K; Liu X; Chi JC; Zhang Y; Qiu F
    J Microbiol Methods; 2021 Jul; 186():106241. PubMed ID: 33992679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low endotoxin recovery and its impact on endotoxin detection.
    Cao Y; Zhang Y; Qiu F
    Biopolymers; 2021 Nov; 112(11):e23470. PubMed ID: 34407207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Endotoxin Recovery-Masking of Naturally Occurring Endotoxin.
    Reich J; Weyer FA; Tamura H; Nagaoka I; Motschmann H
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endotoxin recovery using limulus amebocyte lysate (LAL) assay.
    Bolden JS; Warburton RE; Phelan R; Murphy M; Smith KR; De Felippis MR; Chen D
    Biologicals; 2016 Sep; 44(5):434-40. PubMed ID: 27470947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence against a bacterial endotoxin masking effect in biologic drug products by limulus amebocyte lysate detection.
    Bolden JS; Claerbout ME; Miner MK; Murphy MA; Smith KR; Warburton RE
    PDA J Pharm Sci Technol; 2014; 68(5):472-7. PubMed ID: 25336418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Affecting Reduction of Reference Endotoxin Standard Activity Caused by Chelating Agent/Detergent Matrices: Kinetic Analysis of Low Endotoxin Recovery.
    Tsuchiya M
    PDA J Pharm Sci Technol; 2017; 71(6):478-487. PubMed ID: 28928294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Masking of endotoxin in surfactant samples: Effects on Limulus-based detection systems.
    Reich J; Lang P; Grallert H; Motschmann H
    Biologicals; 2016 Sep; 44(5):417-22. PubMed ID: 27464990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological Activity of Masked Endotoxin.
    Schwarz H; Gornicec J; Neuper T; Parigiani MA; Wallner M; Duschl A; Horejs-Hoeck J
    Sci Rep; 2017 Mar; 7():44750. PubMed ID: 28317862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipopolysaccharide Structure and the Phenomenon of Low Endotoxin Recovery.
    Gorman A; Golovanov AP
    Eur J Pharm Biopharm; 2022 Nov; 180():289-307. PubMed ID: 36272656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of limulus amebocyte lysate and recombinant endotoxin alternative assays for an assessment of endotoxin detection specificity.
    Dubczak J; Reid N; Tsuchiya M
    Eur J Pharm Sci; 2021 Apr; 159():105716. PubMed ID: 33454378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Validation Study of the Limulus Amebocyte Lysate Test as an End-Product Endotoxin Test for Polyvalent Horse Snake Antivenom.
    Sheraba NS; Diab MR; Yassin AS; Amin MA; Zedan HH
    PDA J Pharm Sci Technol; 2019; 73(6):562-571. PubMed ID: 30770487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the kinetics and mechanism of low endotoxin recovery in a matrix for biopharmaceutical drug products.
    Reich J; Tamura H; Nagaoka I; Motschmann H
    Biologicals; 2018 May; 53():1-9. PubMed ID: 29685804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial Endotoxin Testing-Fast Endotoxin Masking Kinetics in the Presence of Lauryldimethylamine Oxide.
    Bech Ørving R; Carpenter B; Roth S; Reich J; Kallipolitis B; Sonne-Hansen J
    Microorganisms; 2020 Nov; 8(11):. PubMed ID: 33158205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the rabbit pyrogen test and Limulus amoebocyte lysate (LAL) assay for endotoxin in hepatitis B vaccines and the effect of aluminum hydroxide.
    Park CY; Jung SH; Bak JP; Lee SS; Rhee DK
    Biologicals; 2005 Sep; 33(3):145-51. PubMed ID: 16055344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific assay for endotoxin using immobilized histidine, Limulus amoebocyte lysate and a chromogenic substrate.
    Nawata M; Minobe S; Hase M; Watanabe T; Sato T; Tosa T
    J Chromatogr; 1992 Apr; 597(1-2):415-24. PubMed ID: 1517345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.